Literature DB >> 32499083

Standardizing Opioid Prescriptions to Patients After Ambulatory Oncologic Surgery Reduces Overprescription.

Nkechi J Fearon, Nicole Benfante, Melissa Assel, Gregory T Chesnut, Andrew Vickers, Marcia Levine, Vance Broach, Brett A Simon, Rebecca Twersky, Vincent P Laudone.   

Abstract

BACKGROUND: Overprescribing of opioids after surgery contributes to long-term abuse. Evaluating opioid prescription patterns and patient-reported opioid use offers an evidence-based method to identify potential overprescription. This quality improvement initiative aimed to reduce and standardize opioid prescriptions upon discharge from an ambulatory oncologic surgery center and evaluate the effect of this change on patients' subsequent opioid use and reported pain.
METHODS: Between March 2018 and January 2019, consecutive opioid-naïve patients aged ≥ 18 years who underwent robotic or laparoscopic hysterectomy, radical prostatectomy, or partial nephrectomy, or total mastectomy with or without immediate reconstruction were surveyed 7-10 days postoperatively. Data collected in the pre- (n = 551) and post-standardization (n = 480) cohorts included perception of pain relief, opioids prescribed (verified by electronic medical record review) and consumed, and refills received.
RESULTS: Pre-standardization, the median opioid prescription at discharge was 20 pills (interquartile range [IQR] 20-28) or 140 oral morphine milligram equivalents (MME) (IQR 100-150). Median opioid consumption was 2 pills (IQR 0-7) or 10 MME (IQR 0-40) among all services. Opioid prescriptions were later standardized to 7, 8, and 10 pills (35, 40, and 75 MME), in the gynecology, urology, and breast services, respectively. The change was not associated with an increase in reported pain. Refill requests increased postintervention across all surgeries from 4.4% to 7.7%, with the largest increase among patients who underwent breast surgery.
CONCLUSION: The number of opioid pills given at discharge to patients undergoing ambulatory or short-stay cancer surgery can safely be reduced.
Copyright © 2020. Published by Elsevier Inc.

Entities:  

Year:  2020        PMID: 32499083     DOI: 10.1016/j.jcjq.2020.04.004

Source DB:  PubMed          Journal:  Jt Comm J Qual Patient Saf        ISSN: 1553-7250


  5 in total

1.  An Enhanced Recovery After Surgery protocol for robotic-assisted laparoscopic nephrectomies utilizing a quadratus lumborum block.

Authors:  Wesley Yip; Andrew B Chen; Cristin Malekyan; William Widjaja; Kevin Yan; Makela Stankey; Xue Sun; Akbar N Ashrafi; John N Graham; Shane C Dickerson; Mohamed H Eloustaz; Mihir M Desai; Inderbir S Gill; Monish Aron; Michael P Kim
Journal:  J Robot Surg       Date:  2022-02-10

Review 2.  Opioid Use Consequences, Governmental Strategies, and Alternative Pain Control Techniques Following Total Hip Arthroplasties.

Authors:  Kevin Berardino; Austin H Carroll; Daniel Popovsky; Robert Ricotti; Matthew D Civilette; William F Sherman; Alan D Kaye
Journal:  Orthop Rev (Pavia)       Date:  2022-05-31

3.  Characterization of Symptoms after Radical Prostatectomy and Their Relation to Postoperative Complications.

Authors:  Matthew B Clements; Amy L Tin; Connie L Estes; Ghalib Jibara; Priyanka K Desai; Behfar Ehdaie; Karim A Touijer; Peter T Scardino; James A Eastham; Melissa J Assel; Andrew J Vickers; Brett A Simon; Vincent P Laudone
Journal:  J Urol       Date:  2021-09-21       Impact factor: 7.600

4.  A prospective feasibility study evaluating the 5x-multiplier to standardize discharge prescriptions in cancer surgery patients.

Authors:  Timothy P DiPeri; Timothy E Newhook; Ryan W Day; Yi-Ju Chiang; Whitney L Dewhurst; Elsa M Arvide; Morgan L Bruno; Christopher P Scally; Christina L Roland; Matthew H G Katz; Jean-Nicolas Vauthey; George J Chang; Brian D Badgwell; Nancy D Perrier; Elizabeth G Grubbs; Jeffrey E Lee; Ching-Wei D Tzeng
Journal:  Surg Open Sci       Date:  2022-04-25

5.  Evaluating the effectiveness of email-based nudges to reduce postoperative opioid prescribing: study protocol of a randomised controlled trial.

Authors:  Allison Kirkegaard; Zachary Wagner; Louis T Mariano; Meghan C Martinez; Xiaowei Sherry Yan; Robert J Romanelli; Katherine E Watkins
Journal:  BMJ Open       Date:  2022-09-19       Impact factor: 3.006

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.